Group 1 - Company recently announced the commercialization of OC-01, a nasal spray product for increasing tear secretion in dry eye patients, marking it as the only approved product of its kind in China [1] - Dry eye disease is a common chronic ocular surface condition in China, with an estimated prevalence of 21%-30%, affecting approximately 360 million people [1] - The innovative nasal delivery method of OC-01 significantly improves natural tear secretion and is expected to enhance patient compliance due to its ease of use compared to traditional eye drops [1] Group 2 - Company has established a strategic focus on the ophthalmology field, developing a comprehensive portfolio of innovative drugs for various eye conditions, with multiple products expected to be approved in the next three years [2] - Recent FDA approval for DOORwaY90, a yttrium-90 microsphere injection, allows it to treat unresectable hepatocellular carcinoma (HCC) without size restrictions, making it the first product to receive such dual indications [2] - The international multi-center Phase III clinical trial for CBT-001, an innovative drug for treating pterygium, has successfully completed patient enrollment [2] Group 3 - On July 17, the company's stock rose by 5.13%, closing at HKD 9.83 per share, with a cumulative increase of over 64% from May 1 to July 17 [3]

Group 1 - Tigermed announced the sale of its stake in Lixin Pharmaceutical, holding a direct stake of 3.41% and an indirect stake of 4.58% through fund holdings, with the total transaction valued at approximately $34.11 million [1] - The sale reflects Tigermed's ability to achieve investment returns and demonstrates its professional post-investment management capabilities as a leading CRO [1] Group 2 - Yuan Da Pharmaceutical's innovative nasal spray product for dry eye treatment, OC-01, has received approval from the National Medical Products Administration and its first commercial prescriptions have been implemented [2] - The product's launch enhances Yuan Da's ophthalmology pipeline and signifies its strategic shift from a traditional pharmaceutical company to an innovative one, with future market performance being promising [2] Group 3 - China Pharmaceutical's general manager, Hu Huidong, has resigned due to work adjustments, which may lead to new development strategies if a new management team with rich industry experience is appointed [3] - The impact of this leadership change should be evaluated in conjunction with the company's fundamentals and subsequent announcements [3] Group 4 - Microchip Biotech expects a significant increase in net profit by 173% for the first half of 2025, with revenue projected at 407.29 million yuan, a 35% year-on-year increase [4] - The company is entering a harvest phase due to its independent R&D capabilities, validating its "small but beautiful" commercialization path, although it must continue to advance its pipeline and manage potential policy risks for sustained growth [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 補充公告 持續關連交易 商業合作協議 茲提述遠大醫藥集團有限公司（「本公司」）於2025年4月25日就商業合作協議項下擬進 行的持續關連交易刊發的公告（「該公告」）。除非另有定義，本公告中使用的詞彙與該 公告中的詞彙具有相同意義。 本公司謹就商業合作協議下擬進行的持續關連交易提供以下補充資料。 研發項目詳情 基於本集團與 Sirtex Group之間良好的合作關係，雙方均認可彼此在製藥業的優勢和 專業知識。雙方共同致力於創新，並尋求在開發不透射線產品方面探索潛在的合作機 會。因此，本集團與 Sirtex Group 簽署了《商業合作協議》，以促進雙方在醫藥產品研 發方面的合作。此類研發合作將涉及共享勞動力和實驗室、採購原材料和耗材、在必 要時採購研究 ...

Group 1: Company Developments - The company has received FDA approval for its innovative drug SIR-Spheres® for treating unresectable hepatocellular carcinoma (HCC) [1] - The company’s nasal spray product OC-01 for dry eye syndrome has been approved in mainland China and has begun commercial prescriptions [1][3] - OC-01 is the only nasal spray approved for treating dry eye syndrome in China, providing a new treatment option for patients [1] Group 2: Market Insights - The dry eye syndrome market in China is estimated to have around 360 million patients, with a prevalence rate of approximately 21.0% to 52.4% [3] - The overall dry eye syndrome market in China has a compound annual growth rate (CAGR) of 1.6% from 2017 to 2021, with moderate growth expected in the coming years [4] - The global dry eye syndrome market is projected to reach $25.48 billion in 2024, expanding at a CAGR of 3.4% to $33.26 billion by 2033 [6] Group 3: Product Advantages - OC-01 utilizes a nasal delivery method that enhances tear secretion and improves tear film stability, potentially increasing patient compliance compared to traditional eye drops [7] - The product has shown strong commercial potential, with over 97,000 prescriptions in the U.S. within its first year and approximately $42 million in sales revenue in 2023 [7] - The company has a comprehensive pipeline of innovative ophthalmic products, including treatments for various eye conditions, which are expected to contribute to future revenue growth [11][14] Group 4: Competitive Landscape - The ophthalmic drug market in China has grown from 15.1 billion RMB in 2016 to 18.8 billion RMB in 2020, with a projected market size of 44 billion RMB by 2025 [8] - The company is strategically positioned in the competitive ophthalmic market, focusing on innovative product development to maintain its leading position [10] - The company has established a professional marketing team and a nationwide distribution network to support its ophthalmic product sales [14]

Group 1 - The company has launched OC-01, a nasal spray for increasing tear secretion in dry eye patients, marking a significant milestone in the treatment of dry eye syndrome in China [1] - OC-01 is the first and only nasal spray approved for treating dry eye symptoms globally, having received approval in the US in October 2021 and in mainland China in November 2024 [1] - The product is expected to provide a new treatment option for dry eye patients in China, enhancing the company's position in the ophthalmic market [1] Group 2 - The company focuses on ophthalmology as a key strategic development direction, emphasizing innovation in ophthalmic drugs and enhancing market competitiveness [2] - A comprehensive product system has been established, with multiple innovative products targeting conditions such as myopia, dry eye syndrome, and post-operative inflammation [2] - The company is committed to advancing innovative products and technologies, aiming to meet unmet clinical needs and expand its product pipeline through a global operational strategy [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性公告 本集團治療乾眼症的全球首創鼻噴產品 OC-01 正式獲批後 在中國大陸實現首批商業化處方落地 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) （股份代號: 00512） 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，近日，本集團全球首創用於增加乾眼症患者淚液分泌的鼻噴產品酒石 酸伐尼克蘭鼻噴霧劑(「OC-01」)，在正式獲批後於中山大學附屬第一醫院和深圳市眼科 醫院實現中國大陸首批商業化處方落地。這一裡程碑進展標誌著中國乾眼症治療迎來全 新選擇：中國目前唯一一款獲批上市的用於增加乾眼症患者淚液分泌的鼻噴產品正式投 入臨床應用，為中國乾眼症患者提供一種全新的治療方案。 OC-01 是高選擇性的煙鹼乙酰膽鹼受體激動劑，普遍認為可通過啟動三叉 ...

Core Insights - The Yttrium-90 microsphere injection, 易甘泰®, has benefited over 3,000 liver cancer patients since its launch in mainland China in 2022, showcasing its significant impact in the treatment of liver tumors [1] - The product received FDA approval for a new indication for unresectable hepatocellular carcinoma (HCC) on July 7, 2025, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1][5] - The 15 abstracts related to Yttrium-90 microspheres presented at the 15th Asia-Pacific Primary Liver Cancer Expert Alliance (APPLE) conference highlight its clinical applicability and effectiveness across different stages of HCC [4][2] Group 1: FDA Approval and Clinical Impact - The FDA's early approval was based on the promising mid-term results of the DOORwaY90 clinical trial, which reported an objective response rate of 98.5% and a local tumor control rate of 100% [4][5] - The approval aligns with real-world data from Chinese patients, indicating broad applicability of 易甘泰® in local clinical settings [4] - The product's success is expected to accelerate its commercialization in China and reshape the treatment landscape for liver cancer [1][5] Group 2: Market Context and Future Prospects - According to GLOBOCAN 2022, liver cancer is the sixth most common cancer globally, with approximately 870,000 new cases and 760,000 deaths annually [6] - In China, liver cancer accounted for about 370,000 new cases in 2022, representing 42.5% of global cases, and the mortality rate was approximately 320,000, also the highest globally [6][8] - The Chinese liver cancer drug market is projected to grow at a compound annual growth rate (CAGR) of 12.3%, reaching 45.21 billion yuan by 2030 [8][9] Group 3: Company Development and Innovation - The company has established a comprehensive nuclear medicine industry chain, covering research, production, sales, and regulatory qualifications, with 15 innovative products in the pipeline targeting various cancers [11][17] - The newly launched Chengdu Wenjiang nuclear medicine R&D and production base, with an investment exceeding 3 billion yuan, aims to enhance production capabilities and meet domestic and international demands [17][19] - The base features advanced automation and a full-process radiation monitoring system, positioning the company as a leader in the nuclear medicine sector [18][19]

Investment Rating - The report maintains a positive outlook on the innovative drug sector, expecting significant revenue growth and potential profitability for several companies in the first half of 2025 [3][8]. Core Insights - The innovative drug sector is projected to see revenue growth of at least 40% year-on-year for companies such as BeiGene, Innovent Biologics, and others, driven by the commercialization of core products [3][8]. - The Pharma sub-sector is expected to experience a revenue growth rate of 10-15% for companies like Hansoh Pharmaceutical and China Biologic Products, while others may see growth of 5-10% [3][8]. - The medical services sector is anticipated to have a revenue growth of 15-20% for companies like GuoShengTang, with a focus on mergers and acquisitions [3][8]. Summary by Sections Innovative Drugs - Companies expected to achieve over 40% revenue growth in 1H25 include BeiGene, Innovent Biologics, and others, primarily due to the commercialization of key products [3][8]. - Some companies, such as BeiGene and Innovent Biologics, are likely to reach profitability due to increased sales volume [3][8]. - The report highlights that companies like Hutchison China MediTech may see significant profit growth due to asset disposals [3][8]. Pharma - The impact of centralized procurement is gradually diminishing, allowing for continued innovation and transformation within the sector [3][8]. - Companies projected to achieve 10-15% revenue growth include Hansoh Pharmaceutical and China Biologic Products, while others like 3SBio and United Laboratories may see 5-10% growth [3][8]. Medical Services - GuoShengTang is expected to have a revenue growth of 15-20% in 1H25, with ongoing attention to domestic and international acquisition activities [3][8].

Summary of YD Pharma Conference Call Company Overview - YD Pharma's total assets reached HKD 24.9 billion in 2024, with revenue of HKD 11.64 billion and net profit attributable to shareholders of HKD 2.47 billion, marking a 17.7% year-on-year growth in the pharmaceutical segment [2][5] - The company operates in three main areas: nuclear medicine for oncology, cardiovascular intervention technology, and formulation technology [2][6] Financial Performance - In 2024, YD Pharma's revenue grew by 12.8% year-on-year in RMB terms, with a net profit increase of 34% [4] - The company declared a dividend of HKD 910 million, with a net profit of HKD 1.76 billion excluding fair value changes [5] - The nuclear medicine and cardiovascular intervention segments saw a revenue increase of 148.3% [2][6] Business Segments Nuclear Medicine - The nuclear medicine segment has established a global integrated production and research layout, with significant revenue from the Hepatocyte Injection reaching nearly HKD 500 million [2][7] - The Chengdu production base was completed, enhancing production capabilities for all research pipeline products [7][30] Cardiovascular Intervention - The company focuses on both acute rescue and chronic disease management, with products like Coenzyme Q10 and a second-generation aldosterone receptor antagonist contributing to growth [12] Respiratory and Critical Care - The core product, Ceno, continues to lead the oral market, with plans for various inhalation formulations [9] - A new nasal spray for allergic rhinitis, Raltex, is set to launch in 2025 [9] Research and Development - YD Pharma has 15 innovative products in the registration phase, covering five collaborative projects and seven cancer types [8] - Three products are in Phase III clinical trials, with one international multi-center trial already submitted for approval [8] Sepsis Treatment - Sepsis is a major focus, with YD Pharma's product SC3,141 targeting the overactive immune response associated with the condition [10][11] - The company plans to advance research in this area, addressing a significant public health issue [10] Market Potential - The FDA approved a new indication for the 190 microsphere product for primary liver cancer, expected to significantly boost global sales, particularly in China [16][19] - The domestic sales peak for this product is projected to reach at least RMB 5 billion due to the high incidence of liver cancer in China [19][34] Future Outlook - YD Pharma anticipates a challenging year in 2025 due to the impact of the tenth batch of centralized procurement, but aims for positive revenue growth [39] - The company expects to achieve higher growth rates in 2026, potentially reaching double-digit growth [39] Additional Insights - The Chengdu production base is designed to meet high safety standards and will support the nuclear medicine segment's growth [30] - YD Pharma is exploring partnerships for global sales of its nuclear medicine products, aiming to compete with larger pharmaceutical companies [36][37]

Group 1 - Tong Ren Tang's Executive Vice President Zhang Chunyou submitted a resignation letter, effective July 8, 2025, due to work adjustments, while remaining as General Manager of Tong Ren Tang Technology [1] - The company stated that Zhang Chunyou's departure will not adversely affect daily operations, indicating limited market impact from this internal personnel adjustment [1] Group 2 - Basestone Pharmaceuticals announced an exclusive strategic partnership with Istituto Gentili for the commercialization of Sugliant in Western Europe and the UK, granting Gentili exclusive rights in 23 countries [2] - Basestone will receive up to $192.5 million in payments, including upfront, registration, and sales milestone payments, along with nearly 50% revenue sharing from net sales in the authorized region [2] - This collaboration enhances Basestone's international market recognition and strengthens investor confidence in future growth [2] Group 3 - Fosun Pharma announced guarantees for its subsidiaries, providing a maximum joint liability guarantee for a financing application not exceeding 500 million yuan with Bank of China [3] - Additionally, a guarantee was provided for a financing contract not exceeding 150 million yuan with China Construction Bank for its subsidiary Hanlin Pharmaceutical [3] - This move supports subsidiaries in obtaining funds for business expansion or R&D, although it introduces certain financial risks [3] Group 4 - Run Da Medical responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing issues related to operating performance, goodwill, short-term solvency, and prepayments [4] - The response aims to alleviate market concerns and stabilize investor confidence, although ongoing monitoring of the company's performance improvement measures is necessary [4] Group 5 - Yuan Da Pharmaceutical announced that its joint venture Sirtex Medical Pty Ltd received FDA approval for SIR-Spheres Yttrium-90 microspheres for treating unresectable hepatocellular carcinoma (HCC) [5] - This product is the first and only FDA-approved selective internal radiation therapy for both unresectable HCC and colorectal cancer liver metastases [5] - This breakthrough enhances Yuan Da's market position in oncology and boosts investor confidence in future growth [5]